OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
PharmSource Information Services
Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.
CDMOs can claim credit for the robust growth of emerging bio/pharma financings.
The industry will see an impact from financing, M&As, advanced therapies, generic drugs, and the retail market in 2018.
Recent acquisitions are creating CDMOs with scale that rivals global bio/pharma.
Mergers and acquisitions are positive for the CDMO industry, but there is a downside.
How has the bio/pharmaceutical contract manufacturing industry evolved and changed over the years and what does the future hold?
CMOs may be gaining as strategic partners to large bio/pharma companies, but they have a much harder path to navigate.
Moving global manufacturing operations may be more complicated than it appears.
Robust venture capital investment gives CDMOs and CROs a positive outlook for 2017.
CMO executives are focusing on M&A activity, new business models, and fundraising limits.
The strategies of a innovation-driven CMO may be different than a capacity-driven CMO.